Sugi Predict

Sugi Predict / Compounds / SCHEMBL1949534

SCHEMBL1949534

SCHEMBL1949534

N=C(N)NC(=O)C=Cc1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.70
▸ HDAC2 Q92769 3/20 0.61
▸ HDAC3 O15379 2/20 0.61
▸ HDAC4 P56524 2/20 0.61
▸ HDAC1 Q13547 2/20 0.61
▸ HDAC8 Q9BY41 2/20 0.61
▸ HDAC6 Q9UBN7 2/20 0.61
▸ KMT2A Q03164 3/20 0.57
▸ MMP1 P03956 4/20 0.56
▸ MMP2 P08253 4/20 0.56
▸ MMP9 P14780 4/20 0.56
▸ EGFR P00533 3/20 0.56
▸ MAOA P21397 1/20 0.56
▸ MAOB P27338 1/20 0.56
▸ MAPT P10636 2/20 0.55
▸ NPC1 O15118 2/20 0.55
▸ RAB9A P51151 2/20 0.55
▸ TDP1 Q9NUW8 1/20 0.55
▸ RECQL P46063 2/20 0.53
▸ POLB P06746 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1949533 1.00 HTT (0.70) HTTHDAC2HDAC3HDAC4HDAC1
Guanidine SCHEMBL27709634 0.98 HTT (0.68) HTTHDAC2HDAC3HDAC4HDAC1
Hydrochloric Acid SCHEMBL5427446 0.98 HTT (0.68) HTTHDAC2HDAC3HDAC4HDAC1
Hydrochloric Acid SCHEMBL5427447 0.98 HTT (0.68) HTTHDAC2HDAC3HDAC4HDAC1
SCHEMBL5431007 0.90 HDAC2 (0.66) HTTHDAC2HDAC3HDAC4HDAC1
SCHEMBL5431008 0.90 HDAC2 (0.66) HTTHDAC2HDAC3HDAC4HDAC1
SCHEMBL5435312 0.88 HDAC3 (0.65) HTTHDAC2HDAC3HDAC4HDAC1
SCHEMBL5435310 0.88 HDAC3 (0.65) HTTHDAC2HDAC3HDAC4HDAC1
SCHEMBL28766189 0.87 HTT (0.55) HTTHDAC2HDAC3HDAC4HDAC1
SCHEMBL27709648 0.87 TRPV1 (0.63) HTTHDAC2HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2617709-B1 Guanidine derivatives as antiviral agents BIOTRON LTD (AU) 2022-11-16 — — EP claimed
US-10472332-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2019-11-12 — — US claimed
US-20170260147-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2017-09-14 — — US claimed
US-20150313909-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2015-11-05 — — US claimed
EP-2617709-A1 Guanidine derivatives as antiviral agents Biotron Limited (AU) 2013-07-24 — — EP claimed
US-20130035328-A1 ANTIVIRAL COMPOUNDS AND METHODS GAGE PETER WILLIAM (AU) 2013-02-07 — — US claimed
CN-101111475-A Antiviral compounds and methods BIOTRON LTD (AU) 2008-01-23 — — CN claimed
US-20070099968-A1 Antiviral compounds and methods BIOTRON LIMITED (AU) 2007-05-03 — — US claimed
EP-1646371-A2 ANTIVIRAL COMPOUNDS AND METHODS Biotron Limited (AU) 2006-04-19 — — EP claimed
WO-2004112687-A2 ANTIVIRAL ACYLGUANIDINE COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2004-12-29 — — WO claimed
EP-2617709-B1 Guanidine derivatives as antiviral agents BIOTRON LTD (AU) 2022-11-16 — — EP disclosed
US-11192863-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2021-12-07 — — US disclosed
US-10472332-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2019-11-12 — — US disclosed
WO-2018129556-A1 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS ARDELYX, INC. (US) 2018-07-12 — — WO disclosed
US-20170260147-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2017-09-14 — — US disclosed
WO-1999040064-A1 BIPHENYLSULFONYL CYANAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS A MEDICAMENT AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 1999-08-12 — — WO disclosed
CN-1212255-A Biphenylsulfonylcyanamides, method for the production thereof and use thereof as medicaments HOECHST MARION ROUSSEL DE GMBH (DE) 1999-03-31 — — CN disclosed
EP-0903339-A2 Biphenylsulfonylcyanamides, process for their preparation and their use as medicaments Hoechst Marion Roussel Deutschland GmbH (DE) 1999-03-24 — — EP disclosed
EP-0855392-A2 Five-membered heterocycles having biphenylsulphonyl substituents, processes for the preparation thereof, their use as medicaments or diagnostic agent and medicaments containing them HOECHST AKTIENGESELLSCHAFT (DE) 1998-07-29 — — EP disclosed
CN-1188760-A Benzidine-sulfuryl radical substitution pentatomic heterocycle, its preparation method, its medicinal and composition HOECHST AG (DE) 1998-07-29 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192863-B2 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 HTT 998/4885HDAC2 621/4885HDAC3 262/4885
US-10472332-B2 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 HTT 998/4885HDAC2 621/4885HDAC3 262/4885
US-20070099968-A1 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 HTT 1300/4885HDAC2 702/4885HDAC3 409/4885
US-20170260147-A1 ANTIVIRAL COMPOUNDS AND METHODS MAVS, ZC3HAV1, EIF2AK2 HTT 998/4885HDAC2 621/4885HDAC3 262/4885
US-20130035328-A1 ANTIVIRAL COMPOUNDS AND METHODS ZC3HAV1, MAVS, EIF2AK2 HTT 1378/4885HDAC2 554/4885HDAC3 293/4885
US-20150313909-A1 ANTIVIRAL COMPOUNDS AND METHODS ZC3HAV1, MAVS, EIF2AK2 HTT 1378/4885HDAC2 554/4885HDAC3 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.